Dr. Eric Raabe of Johns Hopkins University is leading innovative research to tackle ATRT by addressing one of its root causes: faulty gene control that keeps tumor cells locked in an immature, aggressive state.
This preclinical project tests a promising new drug called corin, which targets a key epigenetic protein complex that ATRT cells rely on to survive. By pushing these tumor cells to mature, corin may slow or stop their growth. The research team is also studying corin in combination with decitabine, a drug that helps reset abnormal gene activity, with the goal of making treatment more effective and reducing the risk of relapse.
Supported through a collaborative partnership between the TLC Foundation, Solving Kids’ Cancer, the Bibi Fund, and the Hope4ATRT Foundation, this research represents a hopeful step toward more targeted, durable treatments for children facing ATRT.
